Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biocryst Pharmaceuticals

8.79
+0.03000.34%
Post-market: 8.960.1700+1.93%19:30 EDT
Volume:2.91M
Turnover:25.61M
Market Cap:1.84B
PE:-33.88
High:8.92
Open:8.76
Low:8.72
Close:8.76
Loading ...

BioCryst Pharmaceuticals Appoints Babar Ghias as Chief Financial Officer and Head of Corporate Development

Reuters
·
07 Jul

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

THOMSON REUTERS
·
07 Jul

Biocryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
03 Jul

BioCryst Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
01 Jul

BioCryst price target raised to $15 from $13 at BofA

TIPRANKS
·
01 Jul

BioCryst Pharmaceuticals Is Maintained at Outperform by Wedbush

Dow Jones
·
30 Jun

BioCryst Pharmaceuticals Inc : Wedbush Raises Target Price to $18 From $16

THOMSON REUTERS
·
30 Jun

Wedbush Raises Price Target on BioCryst Pharmaceuticals to $18 From $16, Maintains Outperform Rating

MT Newswires Live
·
30 Jun

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires Live
·
28 Jun

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid China Trade Deal Optimism

MT Newswires Live
·
27 Jun

BioCryst Announces Sale of European Orladeyo® (Berotralstat) Business to Neopharmed Gentili for up to $264 Million

THOMSON REUTERS
·
27 Jun

BioCryst Pharmaceuticals Inc - to Use Proceeds to Retire All Remaining Term Debt

THOMSON REUTERS
·
27 Jun

BioCryst Pharmaceuticals Inc - Neopharmed Gentili to Pay BioCryst $250 Mln Upfront for Orladeyo

THOMSON REUTERS
·
27 Jun

Press Release: BioCryst Announces Sale of European ORLADEYO(R) (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Dow Jones
·
27 Jun

Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB

Zacks
·
26 Jun

BioCryst Pharmaceuticals Price Target Maintained With a $17.00/Share by Needham

Dow Jones
·
25 Jun

Needham Sticks to Its Buy Rating for BioCryst (BCRX)

TIPRANKS
·
25 Jun

5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid Volatility

Zacks
·
25 Jun

BioCryst Pharmaceuticals Inc - New Pdufa Target Action Date Set for December 12, 2025 - SEC Filing

THOMSON REUTERS
·
25 Jun

BioCryst Pharmaceuticals Faces FDA Review Extension for Pediatric ORLADEYO® Application, New Target Date Set for December 2025

Reuters
·
25 Jun